Earnings summaries and quarterly performance for Maze Therapeutics.
Research analysts covering Maze Therapeutics.
Recent press releases and 8-K filings for MAZE.
Maze Therapeutics Reviews 2025 Accomplishments and Prepares for Key Q1 2026 Data Readout
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics achieved significant milestones in 2025, including going public, initiating the MZE829 study for APOL1 kidney disease, releasing additional data for its MZE782 program, and completing a small PIPE financing.
- The company anticipates data from its Horizon study for MZE829 in APOL1 kidney disease by the end of Q1 2026. This data is expected to show a 30% reduction in proteinuria (measured by UACR) in broad APOL1-mediated kidney disease (AMKD) patients, which would be considered clinically significant.
- MZE829 is differentiated from competitors, such as Vertex's inaxaplin, by its dual mechanism of action, which involves both blocking the pore and disrupting its assembly, whereas inaxaplin only blocks the pore.
- Following a successful MZE829 readout, Maze Therapeutics plans to initiate planning for a Phase 2b/3 study. Additionally, the company will begin two Phase 2 studies for its MZE782 program in 2026, building on positive data released in September.
3 days ago
Maze Therapeutics Discusses 2025 Accomplishments and Upcoming MZE829 Data Readout
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics experienced a transformative 2025, marked by going public, initiating its MZE829 study for APOL1 kidney disease, and presenting additional data for MZE782, supported by a PIPE financing.
- The company expects to deliver MZE829 Phase 2 data for APOL1 kidney disease by the end of Q1 2026, with a key target of demonstrating at least a 30% reduction in proteinuria (UACR) in broad AMKD patients.
- MZE829 is differentiated by its dual mechanism of blocking the APOL1 pore and disrupting its assembly, which is believed to offer greater potency compared to competitors.
- Following a successful MZE829 data readout, Maze plans to initiate planning for a Phase 2b/3 study, and also intends to start two Phase 2 studies for MZE782 in 2026 after positive data in September 2025.
3 days ago
Maze Therapeutics Reflects on 2025 Accomplishments and Outlines Key 2026 Objectives
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics experienced a transformative 2025, going public early in the year and initiating a study for MZE829 for APOL1 kidney disease.
- The company anticipates delivering data from its Phase 2 Horizon study for MZE829 (APOL1 kidney disease) by the end of Q1 2026. This study aims to demonstrate clinical proof of concept in broad AMKD patients (with or without diabetes) with a target of at least a 30% reduction in proteinuria (UACR).
- MZE829 is differentiated from competitors like Vertex's inaxaplin by its dual mechanism, which blocks the APOL1 pore and disrupts its assembly, leading to significant potency differentiation.
- In September 2025, Maze Therapeutics released additional data for its second program, MZE782, which was well-received and led to a small PIPE financing. The company plans to start two Phase 2 studies for MZE782 in 2026.
3 days ago
Maze Therapeutics Highlights Upcoming Clinical Milestones for MZE829 and MZE782 Programs
MAZE
New Projects/Investments
- Maze Therapeutics plans to deliver clinical proof of concept data for MZE829 in APOL1-mediated kidney disease (AMKD) in Q1 2026, aiming for a 30% reduction in uACR.
- The company intends to initiate two Phase II studies in 2026 for its MZE782 program: one for PKU and another for chronic kidney disease (CKD).
- In September, MZE782 demonstrated clinical proof of mechanism for PKU with a 40-fold increase in urinary Phe and for CKD by showing an eGFR dip indicative of renal protection.
- Maze Therapeutics is well capitalized to achieve its data catalysts, following a financing round in September.
Nov 20, 2025, 12:00 PM
Maze Therapeutics Outlines 2026 Clinical Milestones and Financial Position
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics is currently enrolling its Phase 2 study for MZE829 in APOL1-mediated kidney disease (AMKD) and anticipates releasing clinical proof of concept data in Q1 2026, with a target of achieving a 30% reduction in UACR.
- Building on strong proof of mechanism data from September 2025, the company plans to initiate two Phase 2 programs in 2026 for MZE782: one for Phenylketonuria (PKU) and another for chronic kidney disease (CKD).
- Maze Therapeutics is well-capitalized to deliver on its upcoming data catalysts, following a September 2025 financing.
Nov 20, 2025, 12:00 PM
Maze Therapeutics Provides Update on Kidney Disease Programs and Upcoming Milestones
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics is developing small molecule precision medicines primarily focused on kidney disease, including APOL1-mediated kidney disease (AMKD).
- Their lead program, Maze 829, an APOL1 inhibitor for AMKD, is expected to have a Q1 2026 readout for clinical proof of concept in broad AMKD (with or without diabetes), targeting at least a 30% reduction in proteinuria. Maze 829 is differentiated by its dual mechanism (blocking the pore and disrupting its assembly) and preclinical potency advantage.
- The company also discussed progress on MAZE 782 (SLC6A19 inhibitor), which demonstrated best-in-class properties for Phenylketonuria (PKU) and an eGFR dip in healthy volunteers for Chronic Kidney Disease (CKD), indicative of renal protection.
- The potential market for AMKD is estimated at at least 250,000 individuals, comparable in size to the IGAN population.
Nov 13, 2025, 7:00 PM
Maze Therapeutics Highlights Upcoming Q1 2026 AMKD Data and 2026 Phase 2 Starts for MZE-782
MAZE
New Projects/Investments
- Maze Therapeutics (MAZE) anticipates Q1 2026 data for its lead APO1 mediated kidney disease (AMKD) program, aiming for a 30% reduction in proteinuria to demonstrate clinical proof of concept in a broad patient population of approximately 250,000 individuals.
- The company's MZE-782 program, targeting SLC6A19, showed promising Phase 1 data in September 2025, indicating potential best-in-class efficacy for Phenylketonuria (PKU) with a 40-fold increase in urinary phenylalanine excretion.
- Maze plans to initiate two Phase 2 studies for MZE-782 in both PKU and Chronic Kidney Disease (CKD) in 2026, with the CKD program aiming to be complementary to SGLT2 inhibitors.
- Maze Therapeutics has sufficient capital from its 2025 IPO and a September financing to independently fund these upcoming milestones.
Nov 12, 2025, 1:00 PM
Maze Therapeutics Reports Q3 2025 Financial Results and Pipeline Progress
MAZE
Earnings
New Projects/Investments
Management Change
- Maze Therapeutics reported a net loss of $30.1 million for the third quarter ended September 30, 2025.
- The company reported $383.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025, providing a cash runway into 2028. This position was strengthened by an oversubscribed private placement in September 2025, which generated approximately $150.0 million in gross proceeds.
- Positive first-in-human data for MZE782 were announced in September 2025, with plans to initiate two Phase 2 trials in phenylketonuria (PKU) and chronic kidney disease (CKD) in 2026.
- Enrollment is ongoing for the Phase 2 HORIZON trial of MZE829, and topline data for initial patients are anticipated by the end of Q1 2026.
- Recent corporate appointments include Misbah Tahir as Chief Financial Officer in September 2025 and Hervé Hoppenot as chairman of the board in October 2025.
Nov 6, 2025, 9:21 PM
Maze Therapeutics Reports Strong Phase I MZE-782 Results, Advancing to Phase II in PKU and CKD
MAZE
Guidance Update
New Projects/Investments
- Maze Therapeutics announced positive Phase I clinical data for MZE-782, which demonstrated an excellent safety profile, predictable pharmacokinetics, and robust target engagement, including up to a 42-fold increase in urinary phenylalanine and 68-fold increase in urinary glutamine by day seven.
- Based on these results, Maze plans to initiate Phase II trials for MZE-782 in both Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) in 2026. The Phase I data also showed an initial eGFR dip, consistent with kidney-protective therapies, supporting its potential in CKD.
- The company provided updates on other pipeline programs, including the ongoing Phase II trial for MZE-829 with initial top-line data expected in Q1 2026, and the May 2024 licensing of MZE-001 to Shionogi & Co. for an upfront payment of $150 million.
- Maze Therapeutics also stated that, with recent financing, its financial runway is expected to extend into 2028 based on its current business plan.
Sep 11, 2025, 12:30 PM
Maze Therapeutics Announces Positive MZE-782 Phase I Results and Advancement to Phase II
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics announced positive Phase I results for MZE-782, demonstrating an excellent safety profile with no serious adverse events, predictable pharmacokinetics (PK), and robust pharmacodynamics (PD) with up to a 42-fold increase in urinary phenylalanine and 68-fold increase in urinary glutamine by day seven.
- Based on these results, Maze plans to initiate Phase II trials for MZE-782 in both PKU and CKD in 2026.
- The company's financial runway is expected to extend into 2028 based on its current business plan, and it previously licensed MZE-001 for Pompe disease to Shionogi & Co. in May 2024 for an upfront payment of $150 million.
- Enrollment for the Phase II trial of MZE-829, a dual mechanism inhibitor for APOL1-mediated kidney disease, is continuing, with initial top-line data expected in Q1 2026.
Sep 11, 2025, 12:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more